Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study.

ABSTRACT:

Background

Epidemiologic evidence for a serum cholesterol-prostate cancer link is mixed. Prostate-specific antigen (PSA) is positively correlated with cholesterol, potentially increasing PSA-driven biopsy recommendations in men with high cholesterol, though biopsy compliance may be lower in men with comorbid conditions. These potential biases may affect PSA-driven biopsy rates and subsequent prostate cancer detection in men with high serum cholesterol. Our objective was to test the association between serum cholesterol and prostate cancer risk in men receiving PSA independent, study-mandated prostate biopsies.

Methods

We conducted a post hoc analysis of data from 4974 non-statin users in REDUCE, a randomized trial in men with elevated PSA and a negative baseline biopsy. Men

SUBMITTER: Jamnagerwalla J 

PROVIDER: S-EPMC6021229 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature